
## Ruochan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2563882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activation of the p62â€Keap1â€NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology, 2016, 63, 173-184.	7.3	1,263
2	HMGB1 in health and disease. Molecular Aspects of Medicine, 2014, 40, 1-116.	6.4	763
3	Metallothioneinâ€1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology, 2016, 64, 488-500.	7.3	462
4	The mechanism of HMGB1 secretion and release. Experimental and Molecular Medicine, 2022, 54, 91-102.	7.7	225
5	Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. Gastroenterology, 2014, 146, 1097-1107.e8.	1.3	200
6	HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon, 2020, 6, e05672.	3.2	118
7	Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases. Molecular Medicine, 2013, 19, 357-366.	4.4	98
8	cAMP metabolism controls caspase-11 inflammasome activation and pyroptosis in sepsis. Science Advances, 2019, 5, eaav5562.	10.3	89
9	High mobility group protein B1 controls liver cancer initiation through yesâ€associated protein â€dependent aerobic glycolysis. Hepatology, 2018, 67, 1823-1841.	7.3	88
10	Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges. Journal of Clinical Virology, 2016, 77, 32-39.	3.1	76
11	The Versatile Gasdermin Family: Their Function and Roles in Diseases. Frontiers in Immunology, 2021, 12, 751533.	4.8	70
12	Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling. Cell Cycle, 2018, 17, 2349-2359.	2.6	52
13	The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. Journal of Immunology, 2016, 196, 4331-4337.	0.8	50
14	A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1. Cell Death and Disease, 2018, 9, 1184.	6.3	43
15	AGER-Mediated Lipid Peroxidation Drives Caspase-11 Inflammasome Activation in Sepsis. Frontiers in Immunology, 2019, 10, 1904.	4.8	26
16	Nuclear DAMP complex-mediated RAGE-dependent macrophage cellÂdeath. Biochemical and Biophysical Research Communications, 2015, 458, 650-655.	2.1	24
17	An M0 macrophage-related prognostic model for hepatocellular carcinoma. BMC Cancer, 2022, 22, .	2.6	24
18	Correlation of Long Noncoding RNA SEMA6A-AS1 Expression with Clinical Outcome in HBV-Related Hepatocellular Carcinoma. Clinical Therapeutics, 2020, 42, 439-447.	2.5	15

RUOCHAN CHEN

#	Article	IF	CITATIONS
19	EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. Journal of Cellular and Molecular Medicine, 2020, 24, 12107-12118.	3.6	14
20	Novel chemokine-like activities of histones in tumor metastasis. Oncotarget, 2016, 7, 61728-61740.	1.8	13
21	SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC. Frontiers in Oncology, 2021, 11, 650355.	2.8	12
22	Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 657051.	2.3	12
23	Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report. BMC Infectious Diseases, 2019, 19, 224.	2.9	7
24	Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive HepatitisÂB Surface Antigen Carriers. Infectious Diseases and Therapy, 2021, 10, 2323-2331.	4.0	6
25	Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases. Frontiers in Medicine, 2021, 8, 709884.	2.6	6
26	Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Frontiers in Medicine, 2021, 8, 796901.	2.6	6
27	Cryptococcemia According to Immune Status: An Analysis of 65 Critical Cases. Infectious Diseases and Therapy, 2021, 10, 363-371.	4.0	3
28	Dynamic Changes in the Immune Response Correlate with Disease Severity and Outcomes During Infection with SARS-CoV-2. Infectious Diseases and Therapy, 2021, 10, 1391-1405.	4.0	2
29	Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Frontiers in Medicine, 2021, 8, 701061.	2.6	2
30	Nomogram prediction of severe risk in patients with COVID-19 pneumonia. Epidemiology and Infection, 2021, 149, .	2.1	1